EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes

Mona Mashayekhi iD, Hui Nian, Dustin Mayfield, Jessica K Devin, Jorge L Gamboa, Chang Yu, Heidi J Silver, Kevin Niswender, James M Luther, Nancy J Brown

Diabetes · 01.01.2024 · 73 (1) · 38-50

DOI: 10.2337/db23-0356 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, online erschienen am 24.10.2023. Verfasst von Mona Mashayekhi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN. Hauptthemen laut MEDLINE: Insulin Resistance, Prediabetic State, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic effects of glucagon-like peptide 1 (GLP-1) receptor agonists are confounded by weight loss and not fully recapitulated by increasing endogenous GLP-1. We tested the hypothesis that GLP-1 receptor (GLP-1R) agonists exert weight loss–independent, GLP-1R–dependent effects that differ from effects of increasing endogenous GLP-1. Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin. The GLP-1R antagonist exendin(9-39) and placebo were administered in a two-by-two crossover study during mixed-meal tests. Liraglutide and diet, but not sitagliptin, caused weight loss. Liraglutide improved insulin sensitivity measured by HOMA for insulin resistance (HOMA-IR), the updated HOMA model (HOMA2), and the Matsuda index after 2 weeks, prior to weight loss. Liraglutide decreased fasting and postprandial glucose levels, and decreased insulin, C-peptide, and fasting glucagon levels. In contrast, diet-induced weight loss improved insulin sensitivity by HOMA-IR and HOMA2, but not the Matsuda index, and did not decrease glucose levels. Sitagliptin increased endogenous GLP-1 and GIP values without altering insulin sensitivity or fasting glucose levels, but decreased postprandial glucose and glucagon levels. Notably, sitagliptin increased GIP without altering weight. Acute GLP-1R antagonism increased glucose levels in all groups, increased the Matsuda index and fasting glucagon level during liraglutide treatment, and increased endogenous GLP-1 values during liraglutide and sitagliptin treatments. Thus, liraglutide exerts rapid, weight loss–independent, GLP-1R–dependent effects on insulin sensitivity that are not achieved by increasing endogenous GLP-1. Article Highlights Metabolic benefits of glucagon-like peptide 1 (GLP-1) receptor agonists are confounded by weight loss and are not fully achieved by increasing endogenous GLP-1 through dipeptidyl peptidase 4 (DPP-4) inhibition. We investigated weight loss–independent, GLP-1 receptor (GLP-1R)–dependent metabolic effects of liraglutide versus a hypocaloric diet or the DPP-4 inhibitor sitagliptin. GLP-1R antagonism with exendin(9-39) was used to assess GLP-1R–dependent effects during mixed meals. Liraglutide improved insulin sensitivity and decreased fasting and postprandial glucose prior to weight loss, and these benefits were reversed by exendin(9-39). GLP-1R agonists exert rapid, weight loss–independent, GLP-1R–dependent effects on insulin sensitivity not achieved by increasing endogenous GLP-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistancePrediabetic StateDipeptidyl-Peptidase IV InhibitorsHumansLiraglutideDipeptidyl Peptidase 4GlucagonDiet, ReducingCross-Over StudiesObesityBlood GlucoseHypoglycemic AgentsSitagliptin PhosphateGlucagon-Like Peptide 1Weight LossGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

LiraglutideDipeptidyl Peptidase 4GlucagonBlood GlucoseHypoglycemic AgentsSitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN.
  • Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN.
  • UCHealth Endocrinology, Yampa Valley Medical Center, Steamboat Springs, CO.
  • Department of Population Health, NYU Grossman School of Medicine, New York, NY.
  • Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN.

ORCID-Profile: Mona Mashayekhi

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Disease
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • American Heart Association
  • National Center for Advancing Translational Sciences

Zitieren

APA

Mashayekhi, M., Nian, H., Mayfield, D., Devin, J. K., Gamboa, J. L., Yu, C., Silver, H. J., Niswender, K., Luther, J. M., & Brown, N. J. (2024). Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes, 73(1), 38-50. https://doi.org/10.2337/db23-0356

Vancouver

Mashayekhi M, Nian H, Mayfield D, Devin JK, Gamboa JL, Yu C, et al. Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes. 2024;73(1):38-50. doi:10.2337/db23-0356

BibTeX
@article{Mashayekhi2024,
  author = {Mashayekhi, Mona and Nian, Hui and Mayfield, Dustin and Devin, Jessica K and Gamboa, Jorge L and Yu, Chang and Silver, Heidi J and Niswender, Kevin and Luther, James M and Brown, Nancy J},
  title = {Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes},
  journal = {Diabetes},
  year = {2024},
  volume = {73},
  number = {1},
  pages = {38--50},
  doi = {10.2337/db23-0356}
}
Kostenlos starten →